"Cancer"

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.

The Royal Marsden Hospital was founded in 1851 and was the first hospital in the world dedicated to cancer. The Royal Marsden Cancer Centre is the largest comprehensive cancer centre in Europe and is regarded as one of the top three cancer centres in the world, treating over 60,000 NHS and self-funded patients each year.

In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.

Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases

It is estimated that ninety percent of deaths from breast cancer are caused by complications from metastasis, so how to effectively stop breast cancer metastasis has long been a hot topic in cancer research.

Generally speaking, mild gastritis, i.e. superficial gastritis, does not increase the risk of gastric cancer, but if not adjusted in time, it may further develop into atrophic gastritis, which is a state of "precancerous lesion".

Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.

According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.

With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.